Drugs / Px563L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02655549 | Dec 2015 → Jun 2017 | anthrax infection | Pfenex, Inc | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Px563L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02655549 ↗ |
| Modality | Vaccine | “The trial investigates Px563L and RPA563, two formulations of a novel anthrax vaccine.” NCT02655549 ↗ |
| Route | Intramuscular | “Px563L, administered as two IM doses 28 days apart” PMID 34544599 ↗ Sep 2021 |